SKIN vs MRVI โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SKIN Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to The Beauty Health Company Class A Common Stock (SKIN) driven by superior Valuation, Growth & Margin, Momentum & Technical while MRVI counters with relative strength in Options & Structure. Fundamentally, SKIN trades at 106.4x Forward P/E with 2.4% operating margin (-2.1% YoY revenue) versus MRVI at N/M Forward P/E and -24.2% operating margin (+10.1% YoY). In options structure, SKIN sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against MRVI sits in BREAKOUT (35th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SKIN Revenue | MRVI Revenue | SKIN Op. Margin | MRVI Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $170M | $140M | 8.1% | 16.8% | MRVI |
| FY2020 | $120M | $280M | -14.4% | 42.2% | MRVI |
| FY2021 | $260M | $800M | -15.4% | 69.4% | MRVI |
| FY2022 | $370M | $880M | -7.1% | 65.0% | MRVI |
| FY2023 | $400M | $290M | -32.9% | -11.0% | MRVI |
| FY2024 | $330M | $260M | -20.3% | -90.9% | SKIN |
| FY2025 | $300M | $190M | -6.9% | -115.9% | SKIN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SKIN | MRVI | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $106.3M | $2.0B | Larger Scale | MRVI |
| Trailing P/E Ratio Valuation | 106.4x | N/M | Lower Multiple | SKIN |
| Forward P/E Ratio Valuation | 106.4x | N/M | Lower Multiple | SKIN |
| Revenue Growth (YoY) Growth | -2.1% | +10.1% | Higher Growth | MRVI |
| Operating Margin (TTM) Profitability | 2.4% | -24.2% | Higher Margin | SKIN |
| Net Profit Margin Profitability | -6.3% | -30.8% | Higher Margin | SKIN |
| Return on Equity (ROE) Capital Efficiency | -30.1% | -29.8% | Higher ROE | MRVI |
| 52-Week Range Position Momentum | 83% ($0โ$18) | 70% ($3โ$9) | Stronger Trend | SKIN |
| Beta / 30D Volatility Risk Regime | -14.22ฮฒ ยท 192% Vol | 1.61ฮฒ ยท 83% Vol | Lower Realized Risk | MRVI |
| Unified Institutional Score Composite Signal | 34.1 / 100 (SELL) | 52.0 / 100 (HOLD) | Higher Composite | MRVI |